Inovio Pharmaceuticals Inc.

4.28-0.4700-9.89%Vol 5.55M1Y Perf -55.48%
Jan 18th, 2022 16:00 DELAYED
BID4.28 ASK4.30
Open4.66 Previous Close4.75
Pre-Market- After-Market4.27
 - -  -0.01 -0.23%
Target Price
13.63 
Analyst Rating
Hold 2.63
Potential %
218.46 
Finscreener Ranking
★★     44.99
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     51.61
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★     47.19
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
0.07 
Earnings Rating
Strong Buy
Market Cap900.45M 
Earnings Date
7th Mar 2022
Alpha0.02 Standard Deviation0.25
Beta0.49 

Today's Price Range

4.274.68

52W Range

4.2719.00

5 Year PE Ratio Range

-9.80-4.80

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.86%
1 Month
-26.92%
3 Months
-32.34%
6 Months
-42.49%
1 Year
-55.48%
3 Years
-6.68%
5 Years
-29.53%
10 Years
182.74%

TickerPriceChg.Chg.%
INO4.28-0.4700-9.89
AAPL169.80-3.2700-1.89
GOOG2 725.81-69.9200-2.50
MSFT302.65-7.5500-2.43
XOM73.081.21001.68
WFC56.69-1.3700-2.36
JNJ167.10-0.7400-0.44
FB318.15-13.7500-4.14
GE102.89-0.2700-0.26
JPM151.27-6.6200-4.19
Financial StrengthValueIndustryS&P 500US Markets
7.80
9.50
0.06
0.07
-86.60
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-3 317.40
-3 250.10
-1 570.70
-
RevenueValueIndustryS&P 500US Markets
935.64K
0.00
-35.67
-34.18
Earnings HistoryEstimateReportedSurprise %
Q03 2021-0.33-0.2912.12
Q02 2021-0.25-0.39-56.00
Q01 2021-0.18-0.27-50.00
Q04 2020-0.22-0.1436.36
Q03 2020-0.18-0.22-22.22
Q02 2020-0.18-0.23-27.78
Q01 2020-0.24-0.26-8.33
Q04 2019-0.23-0.32-39.13
Earnings Per EndEstimateRevision %Trend
12/2021 QR-0.3310.81Positive
12/2021 FY-1.268.70Positive
3/2022 QR-0.29-7.41Negative
12/2022 FY-0.944.08Positive
Next Report Date7th Mar 2022
Estimated EPS Next Report-0.33
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume5.55M
Shares Outstanding210.39M
Shares Float206.95M
Trades Count23.95K
Dollar Volume26.15M
Avg. Volume4.17M
Avg. Weekly Volume3.58M
Avg. Monthly Volume4.70M
Avg. Quarterly Volume4.41M

Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock closed at 4.75 per share at the end of the most recent trading day (a 3.04% change compared to the prior day closing price) with a volume of 4.94M shares and market capitalization of 900.45M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 190 people. Inovio Pharmaceuticals Inc. CEO is J. Joseph Kim.

The one-year performance of Inovio Pharmaceuticals Inc. stock is -55.48%, while year-to-date (YTD) performance is -4.81%. INO stock has a five-year performance of -29.53%. Its 52-week range is between 4.27 and 19, which gives INO stock a 52-week price range ratio of 0.07%

Inovio Pharmaceuticals Inc. currently has a PE ratio of -4.50, a price-to-book (PB) ratio of 2.20, a price-to-sale (PS) ratio of 1 068.07, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.67%, a ROC of -50.14% and a ROE of -57.17%. The company’s profit margin is -%, its EBITDA margin is -3 250.10%, and its revenue ttm is $935.64 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Inovio Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.33 for the next earnings report. Inovio Pharmaceuticals Inc.’s next earnings report date is 07th Mar 2022.

The consensus rating of Wall Street analysts for Inovio Pharmaceuticals Inc. is Hold (2.63), with a target price of $13.63, which is +218.46% compared to the current price. The earnings rating for Inovio Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Inovio Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Inovio Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.98, ATR14 : 0.33, CCI20 : -80.50, Chaikin Money Flow : -0.20, MACD : -0.45, Money Flow Index : 36.02, ROC : -8.65, RSI : 35.16, STOCH (14,3) : 22.22, STOCH RSI : 1.00, UO : 44.87, Williams %R : -77.78), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Inovio Pharmaceuticals Inc. in the last 12-months were: Ann C. Miller (Option Excercise at a value of $0), David B. Weiner (Option Excercise at a value of $54 000), David B. Weiner (Sold 33 583 shares of value $293 430 ), Jacqueline E. Shea (Option Excercise at a value of $362 000), Jacqueline E. Shea (Sold 133 511 shares of value $1 565 908 ), Kim Joseph Jong (Option Excercise at a value of $285 000), Kim Joseph Jong (Sold 162 500 shares of value $2 390 000 ), Laurent Humeau (Option Excercise at a value of $0), Laurent Humeau (Sold 20 635 shares of value $187 985 ), Lota S. Zoth (Option Excercise at a value of $0), Lota S. Zoth (Sold 961 shares of value $4 815 ), Peter D. Kies (Option Excercise at a value of $29 700), Peter D. Kies (Sold 43 750 shares of value $423 038 ), Simon X. Benito (Sold 0 shares of value $-21 360 ), Simon X. Benito (Sold 6 000 shares of value $67 680 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (25.00 %)
2 (25.00 %)
2 (25.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
5 (62.50 %)
5 (62.50 %)
5 (62.50 %)
Moderate Sell
1 (12.50 %)
1 (12.50 %)
1 (12.50 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
2.63
Hold
2.63
Hold
2.63

Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

CEO: J. Joseph Kim

Telephone: +1 267 440-4200

Address: 660 West Germantown Pike, Plymouth Meeting 19462, PA, US

Number of employees: 190

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

100%0%

Bearish Bullish

46%54%

Bearish Bullish

53%47%

TipRanks News for INO

Thu, 16 Dec 2021 00:12 GMT Inovio: Making Progress in the Cervical HSIL Program

- TipRanks. All rights reserved.

Wed, 15 Dec 2021 11:25 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Allogene Therapeutics (ALLO) and Vaccitech Plc (VACC)

- TipRanks. All rights reserved.

Fri, 12 Nov 2021 23:22 GMT Inovio Stock at $35 a Share This Analyst Thinks Its Possible

- TipRanks. All rights reserved.

Thu, 12 Aug 2021 12:41 GMT Inovio: Covid-19 Vaccine Opportunity Still at Play

- TipRanks. All rights reserved.

Wed, 11 Aug 2021 12:45 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Inovio Pharmaceuticals (INO), Moderna (MRNA) and Beauty Health (SKIN)

- TipRanks. All rights reserved.

Tue, 10 Aug 2021 12:30 GMT Inovio Pharmaceuticals Q2 Results Miss Estimates Shares Dip 4.2% Pre-Market

- TipRanks. All rights reserved.

News

Stocktwits